MA51519A - Animaux c5 et c3 humanisés - Google Patents

Animaux c5 et c3 humanisés

Info

Publication number
MA51519A
MA51519A MA051519A MA51519A MA51519A MA 51519 A MA51519 A MA 51519A MA 051519 A MA051519 A MA 051519A MA 51519 A MA51519 A MA 51519A MA 51519 A MA51519 A MA 51519A
Authority
MA
Morocco
Prior art keywords
humanized
animals
Prior art date
Application number
MA051519A
Other languages
English (en)
French (fr)
Inventor
Jingtai Cao
Ying Hu
Adrianna Latuszek
Lynn Macdonald
John Mcwhirter
Karolina Meagher
Alexander Mujica
Andrew Murphy
Stanley Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA51519A publication Critical patent/MA51519A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
MA051519A 2014-05-05 2015-05-04 Animaux c5 et c3 humanisés MA51519A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461988581P 2014-05-05 2014-05-05
US201462067836P 2014-10-23 2014-10-23

Publications (1)

Publication Number Publication Date
MA51519A true MA51519A (fr) 2020-11-11

Family

ID=53177902

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051519A MA51519A (fr) 2014-05-05 2015-05-04 Animaux c5 et c3 humanisés

Country Status (15)

Country Link
US (5) US9795121B2 (enExample)
EP (3) EP3142483B1 (enExample)
JP (1) JP6598798B2 (enExample)
KR (1) KR102461511B1 (enExample)
CN (1) CN106659146B (enExample)
AU (1) AU2015256299C1 (enExample)
BR (1) BR112016025751A2 (enExample)
CA (2) CA2946412C (enExample)
ES (2) ES2968749T3 (enExample)
IL (1) IL248481B (enExample)
MA (1) MA51519A (enExample)
MX (2) MX2016014504A (enExample)
RU (2) RU2713327C2 (enExample)
SG (2) SG11201608696RA (enExample)
WO (1) WO2015171523A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CA2946412C (en) 2014-05-05 2024-02-27 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals
NO2785538T3 (enExample) 2014-05-07 2018-08-04
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
US20190033329A1 (en) * 2016-01-25 2019-01-31 President And Fellows Of Harvard College Methods and compositions for detecting and treating schizophrenia
MY191668A (en) 2016-06-14 2022-07-06 Regeneron Pharma Anti-c5 antibodies and uses thereof
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
SG11201907606XA (en) * 2017-02-27 2019-09-27 Regeneron Pharma Humanized model of kidney and liver disorders
AU2018298039B2 (en) 2017-07-06 2023-02-02 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
CA3071712C (en) * 2017-09-29 2023-02-14 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus and methods of use
CN107736281A (zh) * 2017-09-29 2018-02-27 中国水产科学研究院珠江水产研究所 一种利用益生菌发酵酱油渣防治池塘养殖鳜鱼寄生虫的方法
RU2020112751A (ru) * 2017-09-29 2021-10-29 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, у которых экспрессируется гуманизированный комплекс c1q
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
AU2018392334A1 (en) 2017-12-22 2020-05-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
SG11202005235WA (en) 2018-01-31 2020-07-29 Regeneron Pharma System and method for characterizing size and charge variant drug product impurities
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
CN111771000A (zh) 2018-02-28 2020-10-13 瑞泽恩制药公司 用于鉴定病毒污染物的系统和方法
WO2019182901A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
SG11202008897SA (en) 2018-04-03 2020-10-29 Ngm Biopharmaceuticals Inc C3-binding agents and methods of use thereof
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
SG11202011284RA (en) 2018-07-16 2020-12-30 Regeneron Pharma Non-human animal models of ditra disease and uses thereof
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
EP3846850A4 (en) 2018-09-06 2022-06-15 The Trustees of the University of Pennsylvania HUMANIZED ANTI-C5 ANTIBODIES AND USES THEREOF
EP3857236A1 (en) 2019-01-16 2021-08-04 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
CN117178959A (zh) 2019-04-04 2023-12-08 瑞泽恩制药公司 包括人源化凝血因子12基因座的非人动物
WO2020219922A1 (en) * 2019-04-24 2020-10-29 The Trustees Of The University Of Pennsylvania Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof
KR20220007586A (ko) 2019-05-13 2022-01-18 리제너론 파마슈티칼스 인코포레이티드 개선된 경쟁적 리간드 결합 검정
JP7610339B2 (ja) 2019-06-04 2025-01-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ベータスリップ変異を有するヒト化ｔｔｒ遺伝子座を含む非ヒト動物と使用方法
BR112021022722A2 (pt) 2019-06-07 2022-01-04 Regeneron Pharma Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
IL317159A (en) 2019-09-24 2025-01-01 Regeneron Pharma Systems and methods for use in chromatography and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN114760986A (zh) 2019-11-25 2022-07-15 里珍纳龙药品有限公司 使用非水性乳液的持续释放调配物
MX2022008973A (es) 2020-01-21 2022-08-11 Regeneron Pharma Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
CA3191836A1 (en) 2020-10-01 2022-04-07 Andrew J. Murphy Rodent animals expressing human cr1
US12239687B2 (en) 2020-11-25 2025-03-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
CA3202197A1 (en) 2021-01-20 2022-07-28 Reginald Smith Methods of improving protein titer in cell culture
EP4302098A1 (en) 2021-03-03 2024-01-10 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
EP4315344A1 (en) 2021-03-26 2024-02-07 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
CA3220848A1 (en) 2021-06-01 2022-12-08 Timothy Riehlman Microchip capillary electrophoresis assays and reagents
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
US20230090912A1 (en) 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
IL311248A (en) 2021-10-07 2024-05-01 Regeneron Pharma PH meter calibration and repair
US20230116199A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
KR20240097864A (ko) 2021-10-26 2024-06-27 리제너론 파마슈티칼스 인코포레이티드 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법
CN118251491A (zh) 2021-10-28 2024-06-25 瑞泽恩制药公司 用于敲除C5的CRISPR/Cas相关方法及组合物
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
KR20250124178A (ko) 2022-12-16 2025-08-19 리제너론 파아마슈티컬스, 인크. 크로마토그래피 칼럼의 무결성을 평가하기 위한 방법 및 시스템
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445135A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 液態蛋白質組成物穩定性之建模方法
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
AU2024265540A1 (en) 2023-05-01 2025-10-30 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025122669A1 (en) * 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized complement factor b gene
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
EP1186660A3 (fr) 1985-03-30 2002-03-20 KAUFFMAN, Stuart A. Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
DE69130831T2 (de) 1990-11-21 1999-09-16 Iterex Pharmaceuticals Ltd. Partnership, San Diego Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6166288A (en) * 1995-09-27 2000-12-26 Nextran Inc. Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
GB9521943D0 (en) 1995-10-26 1996-01-03 Univ Hertfordshire Coded particles for process sequence tracking in combinatorial compound library preparation
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6280946B2 (en) 1998-08-07 2001-08-28 Boston Probes, Inc. PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya
WO2000039585A1 (en) 1998-12-28 2000-07-06 Sunesis Pharmaceuticals, Inc. Identifying small organic molecule ligands for binding
WO2005060739A1 (en) * 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
BRPI0506629A (pt) 2004-02-10 2007-05-02 Univ Colorado inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
ES2667169T3 (es) 2004-10-19 2018-05-09 Regeneron Pharmaceuticals, Inc. Método para generar un animal no humano homocigótico para una modificación genética
EP1976626A2 (en) 2006-01-11 2008-10-08 Novo Nordisk A/S Improved spherical encoded beads
CA2714296A1 (en) * 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd Humanized anti-c5ar antibodies
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES2700852T3 (es) 2009-10-06 2019-02-19 Regeneron Pharma Ratones modificados genéticamente e injerto
CN105861553B (zh) 2011-02-15 2020-08-14 再生元制药公司 人源化m-csf小鼠
DK2663575T3 (en) 2011-10-28 2014-12-15 Regeneron Pharma HUMANIZED IL-6 and IL-6 receptor
HUE035652T2 (en) 2011-10-28 2018-05-28 Regeneron Pharma Genetically modified major histocompatibility complex mice
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
IL307969B1 (en) 2012-09-07 2025-10-01 Regeneron Pharma Genetically modified non-human animals and methods of using them
CA2887706C (en) 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
KR102211267B1 (ko) 2013-02-22 2021-02-04 리제너론 파아마슈티컬스, 인크. 사람화된 주요 조직적합성 복합체를 발현하는 마우스
TR201904342T4 (tr) 2013-10-15 2019-05-21 Regeneron Pharma Hümani̇ze il-15 hayvanlar
AU2014353347B2 (en) 2013-11-19 2020-07-02 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
CA2946412C (en) 2014-05-05 2024-02-27 Regeneron Pharmaceuticals, Inc. Humanized c5 and c3 animals

Also Published As

Publication number Publication date
MX386644B (es) 2025-03-19
CA2946412C (en) 2024-02-27
SG10202003996YA (en) 2020-06-29
AU2015256299B2 (en) 2021-09-23
CA3225091A1 (en) 2015-11-12
RU2713327C2 (ru) 2020-02-04
CN106659146A (zh) 2017-05-10
US10492477B2 (en) 2019-12-03
US20200037587A1 (en) 2020-02-06
SG11201608696RA (en) 2016-11-29
NZ726602A (en) 2024-05-31
ES2968749T3 (es) 2024-05-13
RU2016146390A (ru) 2018-06-06
EP4317445A3 (en) 2024-05-15
US20180332833A1 (en) 2018-11-22
US20220132818A1 (en) 2022-05-05
AU2015256299A1 (en) 2016-12-08
US20150313194A1 (en) 2015-11-05
CA2946412A1 (en) 2015-11-12
EP3636073C0 (en) 2023-11-15
US9795121B2 (en) 2017-10-24
JP2017514496A (ja) 2017-06-08
EP4317445A2 (en) 2024-02-07
NZ763860A (en) 2024-05-31
ES2779070T3 (es) 2020-08-13
EP3142483B1 (en) 2020-01-22
EP3142483A1 (en) 2017-03-22
IL248481A0 (en) 2016-12-29
US20170332611A1 (en) 2017-11-23
CN106659146B (zh) 2020-06-23
KR20170002472A (ko) 2017-01-06
US10524458B2 (en) 2020-01-07
MX2016014504A (es) 2017-05-23
EP3636073B1 (en) 2023-11-15
RU2020103811A (ru) 2020-02-18
AU2015256299C1 (en) 2022-01-06
RU2016146390A3 (enExample) 2018-11-22
EP3636073A1 (en) 2020-04-15
BR112016025751A2 (pt) 2018-01-16
JP6598798B2 (ja) 2019-10-30
KR102461511B1 (ko) 2022-11-01
US11178860B2 (en) 2021-11-23
IL248481B (en) 2021-04-29
WO2015171523A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
NL301117I2 (nl) trastuzumab deruxtecan
MA51519A (fr) Animaux c5 et c3 humanisés
IL284727B (en) Noise suppression methods and apparatus
IL258437B (en) Growing systems and methods
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
LT3097119T (lt) Žmogaus antikūnai prieš pd-1
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3560954T3 (da) Modificeret j-kæde
DK3151875T3 (da) Humane lever-scaffolds
PL3280440T3 (pl) Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
IL291164A (en) Anti-nme antibody
DK3188721T3 (da) Humane terapeutika
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
PL3092003T3 (pl) Nowe przeciwciało przeciw netrynie-1
DK3136845T3 (da) Fjerkræstrøelse
LT3178931T (lt) Anti-orai1 antikūnas
LT3126391T (lt) Hpa-1a antikūnai
DK3235799T3 (da) Oximforbindelse og herbicid
ES1101930Y (es) Pulsera portagomas
DK2965607T3 (da) Såmaskine
TH1601002070A (th) สัตว์ที่ได้รับการฮิวมาไนซ์ด้วย il-15
UA28938S (uk) Маскувальна сітка
TH1601002248A (th) องค์ประกอบฆ่าศัตรูพืชและสัตว์และวิธีที่เกี่ยวข้อง